Fig. 2.

Enrichment on disease signatures based on NAFLD lipidomic studies. Overenrichment (ORA) analysis was performed by integrating the list of query metabolites (Supplemental Table 1) and disease signatures retrieved from the MetaboAnalyst platform based on metabolite sets reported in human blood (A) and human feces (B). ORA was implemented using the hypergeometric test to evaluate whether a particular metabolite set is represented more than expected by chance within the given compound list. One-tailed P-values are provided after adjusting for multiple testing. NAFLD, nonalcoholic fatty liver disease.